Version history

{
  "session_id": "sess_SDA-BIOMNI-SURVIVAL-3e217f4d",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\":[{\"title\":\"APOE ε4 Carriage as Primary Genetic Determinant of Dementia Progression Velocity\",\"description\":\"APOE ε4 remains the strongest validated predictor of time-to-dementia in MCI, operating through multiple pathways including Aβ aggregation, microglial activation, synaptic vulnerability, tau spreading, and vascular dysfunction. Despite critiques regarding amyloid-centric framing and survival bias at the MCI stage, the evidence base is unmatched. The hypothesis survives falsification in amyloid-negative cohorts and across diverse populations. Composite score integrates strong meta-analytic support with acknowledged heterogeneity in age, sex, and ancestry.\",\"target_gene\":\"APOE\",\"composite_score\":0.80,\"evidence_for\":[{\"claim\":\"APOE ε4 is the strongest genetic risk factor for AD; 2-3x greater cortical Aβ burden in carriers\",\"pmid\":\"Corder et al., 1993; Liu et al., 2013\"},{\"claim\":\"Meta-analytic evidence across ADNI, Rotterdam, and independent cohorts\",\"pmid\":\"Genin et al., 2011\"},{\"claim\":\"APOE4 effects on tau spreading independent of amyloid\",\"pmid\":\"Shi et al., 2017; Fortea et al., 2020\"}],\"evidence_against\":[{\"claim\":\"Effects attenuate after age 75-80, reducing discriminative power in older MCI cohorts\",\"pmid\":\"Shinohara et al., 2020\"},{\"claim\":\"Ancestry heterogeneity: weaker or absent effects in African populations\",\"pmid\":\"Farrer et al., 1997; Graff et al., 2022\"}]},{\"title\":\"Hippocampal Atrophy Rate as Downstream Integrator of Pathology Burden and Progression Velocity\",\"description\":\"Annualized hippocampal atrophy rate independently predicts dementia conversion by reflecting the cumulative downstream consequence of Aβ, tau, vascular, and co-pathology burden. It captures individual-specific progression velocity and modifies APOE ε4 risk—ε4 carriers with rapid atrophy convert 4x faster than stable carriers. As an imaging endpoint integrating multiple pathogenic processes, it demonstrates the strongest longitudinal predictive performance in ADNI and independent memory clinic cohorts despite lacking mechanistic specificity as a targetable pathway.\",\"target_gene\":\"N/A (imaging marker)\",\"composite_score\":0.77,\"evidence_for\":[{\"claim\":\"Jack et al. 2013: Hippocampal atrophy rate is strongest independent predictor of conversion in MCI\",\"pmid\":\"Jack et al., 2013\"},{\"claim\":\"Desikan et al.: Atrophy rate modifies APOE4 risk; 4x faster conversion with rapid loss\",\"pmid\":\"Desikan et al., 2012\"},{\"claim\":\"Longitudinal ADNI validation across amyloid-positive and negative MCI\",\"pmid\":\"ADNI Consortium, multiple publications\"}],\"evidence_against\":[{\"claim\":\"Downstream endpoint does not identify upstream drivers or therapeutic targets\",\"pmid\":\"N/A\"},{\"claim\":\"Less specific for AD-type pathology; elevated in vascular dementia, FTLD, DLB\",\"pmid\":\"Harper et al., 2015\"}]},{\"title\":\"CSF Neurofilament Light Chain as Non-Specific Marker of Neurodegeneration Velocity\",\"description\":\"CSF NfL predicts imminent dementia conversion by quantifying axonal injury from multiple etiologies including Aβ, tau, vascular, and TDP-43 pathology. The hypothesis survives as a marker of neurodegeneration 'velocity' but fails the test of specificity—NfL does not distinguish AD-type progression from other neurodegenerative trajectories. The mechanistic claim that NfL captures a 'second hit' necessary for clinical conversion is supported but tautological. Baseline NfL elevation likely reflects disease severity rather than intrinsic progression rate.\",\"target_gene\":\"N/A (CSF biomarker)\",\"composite_score\":0.73,\"evidence_for\":[{\"claim\":\"Mattsson et al. 2019: Elevated NfL predicts 2-3 year conversion in MCI independent of amyloid/tau\",\"pmid\":\"Mattsson et al., 2019\"},{\"claim\":\"Bairakti et al. 2023: NfL reflects injury velocity across etiologies\",\"pmid\":\"Bairakti et al., 2023\"},{\"claim\":\"Captures multi-etiology neurodegeneration including vascular and TDP-43\",\"pmid\":\"Khalil et al., 2020\"}],\"evidence_against\":[{\"claim\":\"Non-specific: rises in any axonal injury (vascular, traumatic, inflammatory); not AD-specific\",\"pmid\":\"Khalil et al., 2018\"},{\"claim\":\"May reflect baseline disease severity rather than independent progression velocity\",\"pmid\":\"Bacioglu et al., 2016\"},{\"claim\":\"Prediction window (2-3 years) is arbitrary; unclear if NfL vs tau/amyloid adds independent value\",\"pmid\":\"Lewczuk et al., 2021\"}]},{\"title\":\"Executive Dysfunction as Non-Specific Correlate of Cognitive Severity Rather Than Independent Progression Driver\",\"description\":\"Baseline EF deficits correlate with faster dementia onset but the hypothesis fails as an independent mechanistic predictor. Critiques demonstrate that EF deficits at baseline likely reflect disease stage, mesial temporal dysfunction affects both EF and memory, and the frontostriatal bypass mechanism is contradicted by tau PET data showing hippocampal-to-frontal progression. EF lacks specificity for AD-type pathology and the mechanistic claim is unsubstantiated. Revised downward from 0.75 to 0.65; EF remains a clinically useful correlate but not an independent driver or mechanistic target.\",\"target_gene\":\"N/A (clinical marker)\",\"composite_score\":0.65,\"evidence_for\":[{\"claim\":\"Banks et al. 2016; Jheng et al. 2022: EF deficits associated with faster MCI progression\",\"pmid\":\"Banks et al., 2016; Jheng et al., 2022\"},{\"claim\":\"Frontostriatal vulnerability in small vessel disease and α-synuclein pathology is biologically plausible\",\"pmid\":\"Jellinger, 2008\"}],\"evidence_against\":[{\"claim\":\"Baseline severity confound: EF deficits reflect disease stage, not independent velocity\",\"pmid\":\"Expert assessment: matched baseline design required",
  "tokens_used": "1411"
}